Glioblastoma specific antigens, GD2 and CD90, are not involved in cancer stemness.
about
Anti-GD2-ch14.18/CHO coated nanoparticles mediate glioblastoma (GBM)-specific delivery of the aromatase inhibitor, Letrozole, reducing proliferation, migration and chemoresistance in patient-derived GBM tumor cells.CD90 a potential cancer stem cell marker and a therapeutic target.Multiple roles of CD90 in cancer.Targeting cancer stem cells by using chimeric antigen receptor-modified T cells: a potential and curable approach for cancer treatment.
P2860
Glioblastoma specific antigens, GD2 and CD90, are not involved in cancer stemness.
description
2015 nî lūn-bûn
@nan
2015 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մարտին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Glioblastoma specific antigens, GD2 and CD90, are not involved in cancer stemness.
@ast
Glioblastoma specific antigens, GD2 and CD90, are not involved in cancer stemness.
@en
type
label
Glioblastoma specific antigens, GD2 and CD90, are not involved in cancer stemness.
@ast
Glioblastoma specific antigens, GD2 and CD90, are not involved in cancer stemness.
@en
prefLabel
Glioblastoma specific antigens, GD2 and CD90, are not involved in cancer stemness.
@ast
Glioblastoma specific antigens, GD2 and CD90, are not involved in cancer stemness.
@en
P2093
P2860
P356
P1476
Glioblastoma specific antigens, GD2 and CD90, are not involved in cancer stemness.
@en
P2093
Bong Gu Kang
Do-Hyun Nam
Jae Yeol An
Kyeung Min Joo
Seon Rang Woo
Young Taek Oh
P2860
P356
10.5115/ACB.2015.48.1.44
P577
2015-03-20T00:00:00Z